top of page

Verve Therapeutics' CEO on today's gene editing clinical trial pause

Sek Kathiresan describes what Verve believes caused elevated liver enzymes and thrombocytopenia in a PCSK9 gene editing trial and why he thinks a new program set to enter the clinic may avoid these issues.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page